Quick Answer
Tempest Therapeutics, Inc. reported Operating Income Loss of -$26.58 million for the year ending 2025.
- Tempest Therapeutics, Inc. showed an increase of +36.8% in Operating Income Loss from 2024 to 2025.
- This data is from Tempest Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), Tempest Therapeutics, Inc.'s Operating Income Loss has declined by 96.4%.
- Historical annual values: Fiscal year 2025: -$26.58 million | Fiscal year 2024: -$42.03 million | Fiscal year 2023: -$29.16 million | Fiscal year 2022: -$34.64 million | Fiscal year 2021: -$26.99 million | Fiscal year 2020: -$19.30 million | Fiscal year 2019: -$45.40 million | Fiscal year 2018: -$26.87 million | Fiscal year 2017: -$84.33 million | Fiscal year 2016: -$81.01 million | Fiscal year 2015: -$72.00 million | Fiscal year 2014: -$47.93 million | Fiscal year 2013: -$29.13 million | Fiscal year 2012: -$13.53 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: